Insider Notice: BorgWarner 3,500-Share Sale via Charles Schwab on NYSE
Rhea-AI Filing Summary
BorgWarner Inc. insider filing shows a proposal to sell 3,500 common shares through Charles Schwab & Co., Inc. on the NYSE with an aggregate market value of $154,632 and an approximate sale date of 09/11/2025. The securities were acquired in 2025 as equity compensation: 2,543 shares from a performance stock lapse on 02/05/2025 and 957 shares from a restricted stock lapse on 02/28/2025. The filer previously sold 13,190 shares over August–September 2025 for total gross proceeds of $534,395. The notice includes the signature representation that no undisclosed material adverse information is known.
Positive
- Acquisitions were equity compensation, indicating sales derive from vested awards rather than market purchases
- Broker and exchange identified (Charles Schwab & Co.; NYSE), supporting orderly execution
Negative
- None.
Insights
TL;DR: This Form 144 reports routine insider disposals of recently vested equity, with prior August sales totaling 13,190 shares for $534,395.
The filing documents a proposed sale of 3,500 shares valued at $154,632 to be executed through Charles Schwab on the NYSE. All reported acquisitions were equity compensation in early 2025, indicating sales relate to recently vested awards rather than open-market purchases. The recent history of multiple sales in August and early September 2025 suggests ongoing disposition of vested holdings. There is no information in this notice about any material nonpublic information or changes to company operations.
TL;DR: Filing appears procedurally compliant under Rule 144, documenting vesting and planned sales with required signer representation.
The Form 144 identifies the seller, the broker, acquisition dates and the nature of acquisition (performance lapse and restricted stock lapse), meeting disclosure expectations for insider sales. The signature statement affirms absence of undisclosed material adverse information. The filing does not disclose any executive departures, trading plan adoption dates, or additional governance actions that would materially change stakeholder oversight.